Dr. Wierda on the Need for Continuous Treatment for CLL

William G. Wierda, MD, PhD
Published: Thursday, May 04, 2017



William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the need for continuous treatments for patients with chronic lymphocytic leukemia (CLL).

One challenge is the need for continuous treatment, states Wierda. If patients recieve a small molecule inhibitor, they have high disease control but they still have measurable disease. If the patient no longer receives the medicine, the disease will continue to grow.

Currently, researchers are aiming to develop non-chemotherapy regimens, either by sequencing the drugs or combinations that will allow for a treatment-free period.
 
SELECTED
LANGUAGE


William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the need for continuous treatments for patients with chronic lymphocytic leukemia (CLL).

One challenge is the need for continuous treatment, states Wierda. If patients recieve a small molecule inhibitor, they have high disease control but they still have measurable disease. If the patient no longer receives the medicine, the disease will continue to grow.

Currently, researchers are aiming to develop non-chemotherapy regimens, either by sequencing the drugs or combinations that will allow for a treatment-free period.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x